Introduction {#s2}
============

Cancers arise from a series of mutations or genomic alterations that provide a cell with an extensive ability to evade pro-apoptotic and growth-inhibitory signals and to be self-sufficient in growth signals that enable them to divide endlessly ([@bib90]). Other genetic alterations in these cells aid angiogenesis, tissue invasion, and metastasis ([@bib41]; [@bib49], [@bib50]). The rarity of cancers and the time needed for them to develop reflect the low probability of any one cell acquiring the correct set and sequence of mutations. In addition, cancer-initiating mutations are likely to arise in primitive tissue stem cells as these naturally self-renew and persist long-term, allowing accumulation of the necessary mutations. Alternatively, transforming events could occur in early progenitors if the mutations confer these cells with self-renewal capacity ([@bib115]). Consistent with this, several groups have experimentally verified that both the resident tissue stem cells and progenitors can serve as cells of origin in hematological cancers as well as in solid tumors.

After establishment and initiation, how a tumor continues to propagate itself is a key question with implications for therapy. The conventional view of tumor propagation has been that most cancer cells have the capability to proliferate extensively and form new tumor cells. This model, however, could not explain why large numbers of cancer cells were needed to initiate cancer in vivo ([@bib20]) and the low frequency of colonies seen when cancer cells were plated in vitro. The fact that tumors are heterogeneous, and have a limited subset of cells with the potential to drive cancer growth, was first demonstrated in acute myeloid leukemia (AML; [@bib18]; [@bib67]). The identification of malignant stem cells in leukemia initiated a search for similar populations in solid tumors, and about a decade later, a small population of cells with tumor-initiating properties were identified in mammary cancers ([@bib2]) and in brain cancers that preferentially gave rise to tumors in immunodeficient mice ([@bib110], [@bib111]).

Similar to stem cells, cancer stem cells (CSCs) have been thought of as cells at the top of a hierarchy of more differentiated cell populations ([Fig. 1 A](#fig1){ref-type="fig"}). CSCs have also emerged as being particularly drug resistant ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib1]; [@bib33]; [@bib48]; [@bib74]; [@bib77]; [@bib102]), another property enriched in stem cells. Beyond the structural similarities between normal stem cells and CSCs in terms of hierarchical organization, another shared hallmark is the utilization of developmental signaling pathways both during initiation and propagation. Shared gene expression patterns of leukemia ([@bib46]) and brain tumor stem cells with their normal counterparts ([@bib130]) suggests that they use and depend on developmental and stem cell programs. Since cancers co-opt normal stem cell signals to promote malignant growth, there is increased interest in targeting these pathways to control disease progression. In this review, we discuss the origin of cancer, highlight the functional characterization of cancer initiating cells/CSCs in established tumors, and describe strategies targeting intrinsic stem cell signals, as well as supportive signals from the niche, in an effort to improve therapeutic outcomes.

![**Normal and CSC hierarchy.** Normal stem cells and CSCs can self-renew and differentiate into more mature cells. **(A)** Normal stem cells generate the progenitors and mature tissues of the body while CSCs generate more cancer cells. **(B)** Tumors treated with chemotherapy can leave residual chemoresistant CSCs that can regrow a tumor, whereas CSC targeted therapy may lead to tumor regression and eventual resolution.](JCB_201911053_Fig1){#fig1}

Cell of origin {#s3}
==============

Hematological malignancies {#s4}
--------------------------

Chronic myeloid leukemia (CML) is the classic example of a disease where the initiating oncogenic event (the BCR-ABL translocation) occurs in the hematopoietic stem cell (HSC). This concept was proposed in the early 1950s because patients were found to have BCR-ABL mutations in multiple hematopoietic lineages ([@bib30]; [@bib120]; [@bib127]). Later experiments confirmed that only BCR-ABL--expressing HSCs and not progenitor cell populations are capable of recapitulating the characteristics of disease in immunodeficient mice ([@bib53]; [@bib86]). Work using mouse models has indicated that BCR-ABL translocations in the HSCs give rise to CML, while those occurring in more committed progenitors lead to the induction of acute lymphoid leukemia (ALL; [@bib72]; [@bib134]), indicating that the differentiation state of the cell of origin can have a significant impact on disease trajectory and signaling dependencies, independent of the driver mutation.

Like CML, the AML founding clone is generally an HSC or an early progenitor ([@bib18]), and paired diagnosis and relapse sequencing show that following therapy, tumor cells with either acquired or preexisting mutations that confer resistance survive selectively ([@bib34]). Work in mouse models of MLL-AF9--driven AML indicate that while both the granulocyte macrophage progenitor and the HSC serve as cells of origin, the HSC-derived cancer more closely resembles the human disease ([@bib63], [@bib64]). Consistent with this observation, HSCs have also been shown to be the cell of origin in human AML in a study where a large cohort of primary human AML patients were sequenced for commonly occurring mutations ([@bib107]). This identified point mutations in the DNA methyltransferase DNMT3A in ∼25% of the samples, of which ∼90% also had a mutation in the NPM1 gene. While the DNMT3A mutation could also be detected in T cells of some patients, NPM1 could not, indicating that DNMT3A changes probably occur in an ancestral cell like the HSC that can give rise to both myeloid and lymphoid lineages. The fact that only the DNMT3A mutation could be detected in the normal HSCs of patients who had received treatment indicated that these were most likely to be the AML cells of origin ([@bib107]). It is of interest to note that DNMT3A ([@bib73]; [@bib85]) and NPM1 ([@bib6]) mutations alone do not generally give rise to leukemia and are associated with more benign diseases such as myeloproliferative neoplasms and myelodysplastic syndrome. Thus, these data indicate that sequential acquisition of mutations leads to the progression of myeloproliferative neoplasms and/or myelodysplastic syndrome to more aggressive diseases such as AML, as has been shown in the context of colon cancers, where mutations in Apc precede those in the Ras allele ([@bib41]; [@bib124]).

Solid cancers {#s5}
-------------

Consistent with the leukemia paradigm, stem/progenitor populations can often serve as the primary cells of origin in solid cancers. For instance, mutations in Wnt signaling, such as loss of APC, can initiate colon cancer, which then progresses with additional mutations such as activation of Ras and phosphoinositide 3-kinase signaling. The low frequency of these mutations and the time taken for disease progression suggest that the initiating mutation is likely to be in the stem cells ([@bib119]; [@bib124]). Experimental verification of this hypothesis has come from mouse models, where APC loss in the intestinal stem cell compartments results in rapid induction of colon adenomas, indicating that these cells can be the cells of origin of cancer ([@bib11]; [@bib99]). Single tumor gland and single-cell sequencing experiments in human colon cancer have since confirmed that most tumors arise from a single clone, which acquires mutations early during cancer initiation ([@bib29]; [@bib113]).

Like colon adenocarcinomas, studies with mouse models have implicated stem cells as cells of origin for squamous cell carcinomas (SCC). Thus, mutations in Kras and p53 ([@bib101]), or loss of Pten and Tgfb signaling ([@bib15]), can drive head and neck SCC only from undifferentiated basal cells of the epithelium. Similarly, overexpression of Stat3 and Sox2 oncogenic signals in undifferentiated basal cells results in esophageal SCC formation, while their expression in more differentiated lineages has no impact ([@bib76]). Consistent with this, overexpression of Kras along with loss of p53 can promote cutaneous SCC formation only if the mutations occur in either the inter-follicular epithelium or the bulge stem cells ([@bib68]; [@bib128]). Since the presence of these mutations in epithelial progenitors or transit-amplifying cells has no impact on SCC initiation, these studies collectively indicate that the undifferentiated basal stem cells are the cells of origin for several types of SCCs.

While mutations in either stem or progenitor cells can give rise to tumors, the resulting tumors can differ. For instance, in mouse models of breast cancer, loss of BRCA1 and p53 in luminal progenitors results in adenocarcinomas resembling human disease, while the same mutations in basal stem cells gives rise to malignant adenomyoepitheliomas, a tumor type rarely seen in BRCA patients ([@bib83]). In other systems, mutations in either progenitors or stem cells result in distinct tumor types; thus, loss of p53, Nf1, and Pten in neural stem cells, neural progenitors, or oligodendrocyte progenitors gives rise to distinct subtypes of glioblastoma ([@bib3]; [@bib4]). These data collectively indicate that the cell of origin has a significant impact on disease type. Interestingly, in some instances, the driver mutations override the cellular context to initiate similar tumor types; thus, activation of hedgehog signaling in either the neuronal stem or precursor cells results in formation of molecularly similar aggressive medulloblastomas ([@bib131]). In addition to stem cells and progenitors, in certain contexts, such as breast cancer and melanoma cell lines, more differentiated cells appear to be able acquire features of stem cells either spontaneously ([@bib22]), or upon expression of epigenetic regulators ([@bib104]). This may indicate that differentiated cells harbor latent potential to acquire properties of stem cells in specific contexts. Collectively, the studies using mouse models of disease or primary human patient samples indicate that while tumors generally arise from normal tissue stem/progenitor cells, the cell of origin as well as the driver mutations can be critical for determining tumor identity ([Fig. 2](#fig2){ref-type="fig"}).

![**The origin of cancers.** **(A)** Cancer can be driven by a variety of changes such as genetic mutations, genome instability, and heterochromatin changes. **(B)** These changes often arise in populations such as stem cells or more mature progenitor cells.](JCB_201911053_Fig2){#fig2}

Cancer stem cells {#s6}
=================

The initial identification and characterization of CSCs relied on prior knowledge of normal tissue stem cells since the markers used to isolate the CSCs were often similar to their normal counterparts, e.g., CD34 in leukemic stem cells (LSC; [@bib46]) and CD133 in brain tumors ([@bib130]). However, it is important to note that surface markers can be divergent between normal and malignant stem cells, and the defining characteristic of a CSC is the functional ability of these cells to give rise to other cell types within the tumor and propagate disease in vivo.

Hematological malignancies {#s7}
--------------------------

The initial experiments defining leukemia stem cells identified a small population (\<1%) within the primary cancer with the ability to engraft disease in immunocompromised mice. This population shared the phenotypic characteristics of normal HSCs (CD34^+^ CD38^--^) and could generate more differentiated CD38^+^ cells, placing it at the top of a hierarchy, much like its normal counterpart ([@bib67]). More recently, it has become clear that these cells can also drive relapse after therapy ([@bib108]). Interestingly, while CML is driven by a population that closely resembles HSCs, the leukemia stem cells in blast crisis CML appear to share characteristics of a common myeloid progenitor cell ([@bib56]), indicating that more committed progenitors may acquire the ability to self-renew and propagate disease ([Fig. 2 B](#fig2){ref-type="fig"}).

The observations above could not account for the genetic diversity observed in several tumors and the idea that cancers evolve genetically with disease progression. To determine the evolution of genetic diversity in the context of functional heterogeneity, an analysis of the Philadelphia Chromosome copy number variations in primary human BCR-ABL^+^ ALL samples was performed to define the ancestry of functional stem cell populations ([@bib89]). These experiments showed that some patients may contain several different clonal clusters of LSC populations that evolve independently and contribute toward genetic diversity. Moreover, they may grow at differential rates in xenograft assays and in the patient and have unique responses to therapy. This clonal diversity within the CSC pool presumably allows the tumor to adapt to different environments and highlights the importance of identifying therapeutic approaches that eliminate all stem cell clones ([@bib89]). One way to achieve this goal would be to understand the signals that sustain these cells and identify common signatures, if any, between these pools. Work in AML has indicated that enhanced stem cell gene expression programs are highly predictive of poor therapeutic response and relapse in patients ([@bib38]; [@bib46]; [@bib108]), and it would be of interest to determine if this also holds true for other hematological diseases.

Solid cancers {#s8}
-------------

Work from hematological malignancies drove interest in the identification of CSCs in solid cancers. Much like the LSCs, glioblastoma CSC populations were first identified using markers of normal neuronal stem cells and were shown to be at the top of a hierarchy with the ability to differentiate unidirectionally to more mature glial cells ([@bib110], [@bib111]). This paradigm is supported by work in several other primary human cancers such as medulloblastoma ([@bib131]), breast ([@bib2]), ovarian ([@bib133]), colon ([@bib91]; [@bib103]), prostate ([@bib26]; [@bib96]), and pancreatic cancer ([@bib51]), as well as SCCs of skin ([@bib35]) and cervix ([@bib7]). While the frequency of cancer-propagating cells in several cancers has been reported to be small, the CSC population may be larger in some cancers, such as melanomas ([@bib17]; [@bib100]), and may become enriched after therapy and in relapse settings. Differences in the projected extent of the CSC fraction may in part be due to the transplant models used and whether the recipients are immunocompromised or immunocompetent.

In some tumors, the CSCs have been found to be heterogenous with several different sub-clones of CSCs marked by different cell surface markers. For instance, in addition to CD133, markers such as stage-specific embryonic antigen 1 and α6-integrin can also identify populations with the ability to initiate tumors in xenograft models ([@bib69]; [@bib112]). Distinct CSC populations have been observed in colon cancers marked by CD133, CD44, CD26, or any combination of the three ([@bib28]; [@bib91]; [@bib94]; [@bib103]). These differences in cell marker profiles indicate that there may be more than one type of CSC population within a given tumor or that CSCs may evolve and acquire different phenotypic markers with disease progression.

The experiments discussed above were largely dependent on transplantation to prove the importance of the CSCs in tumor propagation. To counter criticisms that these may be a transplantation-specific phenomenon, three key studies focused on targeting these subpopulations within autochthonous models to determine whether this led to inhibition of tumor growth. In a mouse model of SCC, the in vivo eradication of the Sox2^+^ CSC population via diphtheria toxin led to complete regression of the tumor ([@bib19]). Similarly, deleting Nestin^+^ stem cells arrested the growth of glioblastomas and sensitized them to chemotherapy ([@bib24]). Interestingly, continuous ablation of Lgr5^+^ colon CSCs not only arrested the growth of primary tumors but also dramatically reduced metastasis ([@bib32]). Collectively, these studies indicate that CSCs are essential for maintaining tumors and driving metastasis and therapy resistance, and support the idea that targeting these cells may significantly improve therapeutic outcomes ([Fig. 1 B](#fig1){ref-type="fig"}).

Cancer stem cells in metastasis {#s9}
-------------------------------

Stem cells and stem cell signals have been implicated in metastatic progression of the tumor from the primary site to a distal location ([@bib23]; [@bib51]; [@bib94]; [@bib7]; [@bib57]; [@bib79]). As cells leave the primary tumor, they undergo an epithelial to mesenchymal transition (EMT) to acquire the characteristics of more mobile mesenchymal cells. Key studies using in vitro breast cancer cells have shown that the acquisition of EMT is accompanied by a transcriptional program indicative of the stem cell state ([@bib79]). These differential transcriptional profiles may be due to inherent changes in the epigenetic landscape of the cell of origin. For instance, the chromatin of genes associated with EMT is more open and accessible in stem cells of SCCs arising from the hair follicle stem cells and not in the less metastatic, more differentiated SCCs that arise from epidermal stem cells ([@bib70]). However, it is also possible that these epigenetic states are more dynamic since SCC cells can express signatures of both the hair follicle and epidermal stem cells at any given point of time, indicating that epigenetic changes can lead to lineage plasticity ([@bib45]).

Consistent with the possibility that metastatic cells harbor stem cell properties, circulating tumor cells with the ability to recreate tumors at a secondary site can also express markers of primary tumor stem cells ([@bib5]). Since cells isolated from the primary tumor using markers such as ALDH have an enhanced capacity to metastasize ([@bib23]), it is likely that the CSCs and metastatic cells have overlapping phenotypic and signaling profiles. This is supported by the observation that in primary pancreatic cancer, cells that express CXCR4 and have the ability to metastasize are a subset of tumor-propagating chemoresistant CD133^+^ CSCs ([@bib51]).

Recent studies interrogating populations undergoing EMT at a single-cell level have confirmed the existence of a continuum of cellular states reflective of a fully epithelial, mesenchymal, or several intermediate EMT states ([@bib82]; [@bib95]). Importantly, the progression of EMT could be halted by disrupting oncogenic developmental signals, such as Ras ([@bib82]), suggesting that the signals sustaining these distinct metastatic populations may all rely on a core network of stem cell programs. A better understanding of the links between CSCs and metastasis could be a new avenue to define strategies to target metastatic progression.

Stem cell signals in cancer {#s10}
===========================

Aberrant activation of signals required for normal development can promote oncogenic transformation. This includes Ptch1 mutations in basal cell carcinoma ([@bib43]), APC mutations in colon cancer ([@bib62]; [@bib87]), and Notch mutations in T-ALL ([@bib36]), all developmental pathways that have also been shown to play a critical role in maintaining normal tissue stem cells. Like their normal counterparts, stem cells from many cancers also rely on these developmental signals to maintain self-renewal and evade chemotherapy ([Fig. 3](#fig3){ref-type="fig"}).

![**Signals sustaining CSCs.** Cancer cells are sustained by developmental signaling pathways and interactions with the niche. ABC, ATP binding cassette; HNSCC, head and neck squamous cell carcinoma; LRP, lipoprotein receptor--related protein; NSCLC, non-small-cell lung carcinoma.](JCB_201911053_Fig3){#fig3}

Hedgehog signaling {#s11}
------------------

Much of the initial work on Hedgehog signaling in cancer was done in brain tumors, where aberrant activation of this pathway is common. An extensive study on gliomas has revealed that Hedgehog-Gli signaling regulates the expansion of CD133^+^ glioma stem cells ([@bib25]; [@bib132]). In addition, this pathway is also elevated in the more primitive, highly proliferative regions of medulloblastomas, and inhibiting Hedgehog signaling can promote apoptosis of medulloblastoma cells ([@bib10]). Thus, there are clinical trials under way to test the impact of Hedgehog inhibitors in medulloblastomas. A similar requirement for active Hedgehog signaling has been reported in pancreatic cancer ([@bib117]) and in multiple myeloma, where blocking this pathway results in the loss of clonal expansion and concomitant differentiation ([@bib97]). In the mammary system, inhibiting Hedgehog signaling reduces not only the ability of mammary CSCs to form primary spheres, but also their ability to self-renew and form secondary spheres ([@bib75]). Hedgehog signaling has been shown to be critical for the maintenance of stem cells in myeloid leukemia ([@bib135]); this and other observations formed the basis of trials testing Hedgehog antagonists in myeloid leukemia and ultimately led to the recent approval for Glasdegib in AML ([@bib88]). Since activated Hedgehog signaling can also up-regulate drug transporters on the surface of CSCs and thus promote chemoresistance ([@bib109]), this pathway may regulate several aspects of the stem cell state and broadly promote cancer progression. It is thus not surprising that inhibitors of this pathway are the most advanced in the clinic.

Wnt signaling {#s12}
-------------

The Wnt signaling pathway was originally identified in breast cancer before its role in development was described. After the original observation that Wnt signaling was activated in breast cancer, it has been linked to multiple other cancers, most notably colon cancer, where 95% of cases harbor mutations in APC. The ability of Wnt signaling to influence stem cells in leukemia was shown in the context of CML, where β-catenin--null mice showed profound defects in the ability to develop BCR-ABL--induced CML ([@bib134]). The few CMLs that did arise were not serially transplantable, highlighting a critical requirement for this pathway for CML stem cell proliferation and self-renewal. Inhibitors of the Wnt pathway targeting the β-catenin*/*CBP interactions (PRI-724) are in trials for aggressive myeloid diseases (NCT01606579). Consistent with the critical role for Wnt pathway mutations in colon cancer initiation and progression, colon CSCs have also been shown to have high Wnt reporter activity, and exogenously activated Wnt can promote the proliferation of these cells ([@bib122]). In addition, Wnt signaling is critical for sustaining aggressive triple-negative breast CSCs ([@bib57]), and several trials such as those with vantictumab (NCT01345201), (LGK974)189 (NCT01351103), and Ipafricept ([@bib59]) have been initiated to target the Wnt pathway in breast cancers.

Notch signaling {#s13}
---------------

Notch signaling has been found to be a critical signal for the development and propagation of multiple cancers including T-ALL, breast cancer, and pancreatic cancer. The possibility that the Notch pathway may have a role in maintaining CSCs was first established in medulloblastomas, where inhibition of Notch cleavage and activation led to a striking reduction in the CD133^+^ CSCs, and a significant loss in their ability grow in vivo ([@bib47]). Consistent with this, the constitutive activation of Notch2 increased the CSC population, and its inhibition completely eradicated stem cells, while leaving the more differentiated populations unaffected ([@bib39]). In addition to medulloblastomas, Notch signaling is essential for the growth and expansion of stem cells from primary glioblastomas both in vitro and in vivo*.* Inhibition of Notch in murine brain implants of human primary gliomas not only led to the depletion of CSCs but also affected endothelial cells, and thus disrupted tumor angiogenesis, leading to a dramatic reduction in tumor growth ([@bib40]). Importantly, Notch signaling can confer radioresistance to the glioblastoma CD133^+^ CSC population, highlighting the critical role of this pathway in brain tumor stem cells ([@bib126]). In pancreatic cancer, Mir-34 microRNA--mediated down-regulation of Notch1/2 results in a significant reduction in both tumor growth and the CD44^+^/CD133^+^ CSC population ([@bib58]; [@bib84]). Consistent with this, Musashi, a regulator of the Numb/Notch signaling axis, marks the chemoresistant CSC populations in pancreatic cancer ([@bib42]) and myeloid leukemias ([@bib54]). Activated Notch signaling is also essential for maintaining the CSC populations in cervical cancers ([@bib7]) and ovarian cancers ([@bib52]), and inhibitors of the Notch ligand Dll4 are currently in trials for aggressive colon and ovarian carcinomas (NCT03035253). Thus, Notch signaling plays a critical role in promoting therapy-resistant CSC populations across malignancies.

Microenvironmental dependencies {#s14}
-------------------------------

While the role of the microenvironment in sustaining solid cancer growth is well established, its contribution in maintaining the CSC populations is only beginning to be explored. CD44-mediated interactions ([@bib60]) of leukemic progenitors with the osteoblast niche can promote chemoresistance ([@bib66]), and osteopontin--CD44 interactions can support glioma stem cells ([@bib98]). Adhesive interactions with the endothelial cells are particularly critical for maintaining brain tumor stem cells ([@bib21]), and the CD98/VLA-4/VCAM1 ([@bib8]) signaling axis between leukemia stem cells and endothelial cells has been shown to be essential for myeloid leukemia propagation in vivo. Since blocking VLA-4--mediated interactions with fibronectin can promote chemosensitivity in AML ([@bib81]), these adhesive interactions are emerging as novel therapeutic targets for aggressive leukemias. New pathways such as Tspan3 are emerging as key points of control for leukemia propagation; these may in part function by mediating interactions of leukemia stem cells with an SDF-1--enriched niche and protecting the undifferentiated state ([@bib65]). Consistent with this, blocking SDF-1/CXCR4 signaling can influence leukemia differentiation ([@bib116]). Clinical trials aimed at defining the impact of blocking CD98 ([@bib16]), CD44 ([@bib123]), and CXCR4 ([@bib80]; [@bib121]) signaling have shown some promise and indicate that better targeting agents and/or combinatorial therapy could be beneficial in controlling disease progression.

Future directions {#s15}
=================

While much has been learned about intrinsic dependencies of CSCs, how they interact with the microenvironment remains largely unknown. Emerging studies on stromal cell populations, such as endothelial cells in leukemias ([@bib8]) and brain tumors ([@bib21]), stromal myofibroblasts in colon cancer ([@bib122]), cancer-associated fibroblasts in lung and breast cancers ([@bib114]), and mesenchymal stromal cells in leukemias ([@bib55]), suggest that stromal cells can support CSCs just as they support normal stem cells ([Fig. 4](#fig4){ref-type="fig"}). New technologies such as single-cell sequencing aimed toward characterizing the stromal cell niche of cancers in its entirety may be critical to providing a framework for experiments aimed at identifying the specific niche of the CSCs.

![**The normal and malignant stem cell niche.** Stem cell interactions with the microenvironment lead to changes in the niche that promote cancer progression. **(A and C)** Normal stem cells reside in niches guided by complex signaling to control their activation and proliferation. **(B)** LSCs induce cell death and aberrant signaling within the bone marrow microenvironment. **(D)** Solid tumor stem cells reside in dense stroma and transformed cells that protect them from chemotherapy. Boxes represent niche cells in A and B or C and D. OB, osteoblast; EC, endothelial cells; CAR, CXCL12-abundant reticular cells; CAF, cancer-associated fibroblasts; MSC, mesenchymal stromal cells; TAM, tumor-associated macrophages.](JCB_201911053_Fig4){#fig4}

In this context, some recent studies have performed extensive single-cell sequencing on both the normal and preleukemic bone marrow stromal cell populations to determine both the niche of normal HSCs and how it is altered with the initiation of cancer ([@bib13]; [@bib129]). These show that during initiation, leukemias disrupt and alter the niche ([@bib13]), consistent with earlier studies showing that CML stem cells can disrupt osteoblast proliferation, leading to increased fibrosis and a supportive growth environment for LSCs at the expense of HSCs ([@bib106]). Similarly, solid cancers can alter the metastatic niche even before colonization ([@bib61]; [@bib27]; [@bib92]). Single-cell sequencing of primary human breast, lung, and pancreatic cancers has revealed heterogeneity not only in the cancer populations but also in immune and other cells of the microenvironment ([@bib12]; [@bib14]; [@bib37]; [@bib71]; [@bib78]; [@bib125]). Defining the spatial localization of CSCs with respect to specific niche cells, and understanding how these interactions contribute to cancer progression and response to therapy, will be exciting future avenues of work.

While there is some debate on the origin, markers, and frequency of CSCs, a large body of literature now shows that there is significant heterogeneity within multiple cancer types and that subpopulations harbor preferential ability to drive tumor initiation, metastasis, and therapy resistance ([@bib44]; [@bib105]; [@bib9]; [@bib118]; [@bib31]). The work discussed here indicates that such cells not only promote cancer progression but also may be able to adapt and grow in different environments. Understanding both the intrinsic signals that maintain these aggressive stem cell populations and the microenvironmental interactions they depend on will be critical in designing multifaceted therapeutic approaches to target aggressive cancers.
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